智慧藥丸市場機會、成長要素、產業趨勢分析及2026-2035年預測

全球智慧藥丸市場預計到 2025 年價值 13 億美元，並將以 11.8% 的複合年成長率成長，到 2035 年達到 39 億美元。

智慧藥丸市場的成長主要受胃腸道疾病日益普遍以及對先進診斷技術（旨在減少侵入性檢查）需求不斷成長的推動。醫療系統正擴大採用數位化和基於感測器的醫療解決方案，以提高患者監測和診斷準確性。數據分析、人工智慧和數位健康平台的進步顯著增強了口服型醫療設備的功能。人工智慧在處理大量患者數據方面發揮著至關重要的作用，使醫療專業人員能夠更有效率地識別健康狀況並實施精準的治療策略。同時，物聯網 (IoT) 技術的整合實現了遠端監測，使醫生無需患者頻繁就醫即可觀察健康指標。這些創新正在改善臨床決策，並提高整個診斷流程的效率。隨著數位醫療技術的不斷發展，智慧藥丸正成為現代醫療系統中非侵入性診斷、病患監測和疾病管理日益重要的工具。

智慧藥丸是一種口服膠囊，內含電子或機械元件，旨在透過消化道進行診斷、監測或治療。吞服後，這些膠囊會自然地通過消化器官系統，並在過程中收集重要的生理數據。推動這項技術普及的主要因素之一是人們對微創醫療程序的需求日益成長。與傳統診斷技術相比，智慧藥丸技術能夠提高患者的舒適度，降低併發症風險，並加快康復速度。微電子、無線通訊和感測器工程技術的不斷進步也增強了這些設備的性能，使其能夠進行即時生理監測，並拓展其潛在的臨床應用。

預計到2025年，該產品細分市場的規模將達到8.028億美元。智慧膠囊配備微型感測器、微處理器和無線通訊技術，可即時傳輸胃腸道健康、治療依從性和疾病進展等數據。這些設備提供了一種便捷、非侵入性的方式來監測體內生理狀態，同時支持精準的藥物傳遞機制。其易用性和先進的功能使其越來越優於傳統的診斷方法。此外，生物相容性材料和先進病患監測技術的日益普及也進一步加速了智慧膠囊的應用。與穿戴式監測設備和數位健康平台的整合也拓展了智慧膠囊在現代醫學中的應用範圍。

預計到2025年，胃部疾病診療市場佔有率將達到44%。由於智慧藥丸在胃部疾病監測和評估中的應用日益廣泛，該領域的重要性日益凸顯。專為胃部評估設計的智慧藥丸技術能夠即時、直覺地觀察和分析消化系統健康狀況。與傳統診斷方法相比，這些設備能夠更精準地檢測和監測胃部疾病，同時最大限度地減少患者的不適感。對胃部疾病精準早期檢測需求的不斷成長，進一步推動了這項技術的應用。此外，感測器精度、成像能力和無線通訊系統的改進也顯著提升了智慧藥丸在胃部診斷的應用效果。

預計到2025年，北美智慧藥丸市場規模將達到5.035億美元，並預計在2026年至2035年間以11.5%的複合年成長率成長。該地區的強勁成長得益於先進的醫療基礎設施、創新醫療技術的廣泛應用以及強大的數位化醫療解決方案。胃腸道疾病和慢性病盛行率的不斷上升持續推動著對先進診斷和監測工具的強勁需求。此外，該地區老年人口的成長也促進了支持疾病早期檢測和持續監測的醫療技術的廣泛應用。成熟的製藥和醫療設備製造商的存在也加速了產業創新。對研發、醫療創新計畫和政府扶持政策的持續投入，進一步推動了北美智慧藥丸市場的穩定擴張。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 胃腸道疾病盛行率增加
    • 智慧藥丸技術的持續改進
    • 對非侵入性診斷工具的需求日益成長
  • 產業潛在風險與挑戰
    • 嚴格的監管要求
    • 設備高成本
  • 市場機遇
    • 與數位健康生態系統的整合
    • 滲透新興市場
• 成長潛力分析
• 監理情勢（基於初步調查）
  • 北美洲
  • 歐洲
  • 亞太地區
• 科技與創新趨勢
  • 目前技術
  • 新興技術
• 價格分析（基於初步調查）
• 投資和資金籌措趨勢
• 人工智慧和生成式人工智慧對市場的影響
• 波特五力分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 業務拓展計劃

第5章 市場估計與預測：依組件分類，2022-2035年

• 產品
  • 膠囊
  • 其他產品
• 病患監測軟體

第6章 市場估計與預測：依目標零件分類，2022-2035年

• 胃
• 小腸
• 冒號
• 食道

第7章 市場估計與預測：依應用領域分類，2022-2035年

• 膠囊內視鏡
• 標靶藥物遞送
• 生命徵象監測

第8章 市場估算與預測：依最終用途分類，2022-2035年

• 醫院
• 診斷中心
• 其他最終用戶

第9章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• ANX Robotica
• Bodycap
• CapsoVision
• Check-Cap
• etectRx
• Intromedic
• Medtronic
• Otsuka Holdings
• Olympus Corporation
• RF Co.

The Global Smart Pills Market was valued at USD 1.3 billion in 2025 and is estimated to grow at a CAGR of 11.8% to reach USD 3.9 billion by 2035.

Growth in the smart pills market is driven by the increasing prevalence of gastrointestinal disorders and the growing demand for advanced diagnostic technologies that reduce the need for invasive procedures. Healthcare systems are increasingly adopting digital and sensor-based medical solutions that improve patient monitoring and diagnostic precision. Technological progress in data analytics, artificial intelligence, and digital health platforms has significantly enhanced the functionality of ingestible medical devices. Artificial intelligence plays an important role in processing large volumes of patient data, allowing healthcare professionals to identify health conditions more efficiently and implement accurate treatment strategies. At the same time, the integration of Internet of Things technologies is enabling remote monitoring capabilities, allowing physicians to observe patient health metrics without requiring frequent hospital visits. These innovations are improving clinical decision-making and enhancing the overall efficiency of diagnostic procedures. As digital healthcare technologies continue to evolve, smart pills are becoming an increasingly important tool for non-invasive diagnosis, patient monitoring, and disease management within modern healthcare systems.

Smart pills are ingestible capsules that contain electronic or mechanical components designed to travel through the gastrointestinal tract for diagnostic, monitoring, or therapeutic purposes. Once swallowed, these capsules move naturally through the digestive system while collecting valuable physiological data. One of the major factors contributing to the adoption of this technology is the growing preference for minimally invasive medical procedures. Compared with traditional diagnostic techniques, smart pill technology offers improved patient comfort, lower risk of complications, and faster recovery. Continuous advancements in microelectronics, wireless connectivity, and sensor engineering have also strengthened the performance of these devices, enabling real-time physiological monitoring and expanding their potential clinical applications.

The product segment generated USD 802.8 million in 2025. Smart capsules are equipped with miniature sensors, microprocessors, and wireless communication technologies that transmit real time data related to gastrointestinal health, treatment adherence, and disease progression. These devices offer a convenient and non-invasive method for monitoring internal physiological conditions while also supporting precise drug delivery mechanisms. Their ease of use and advanced functionality have contributed to their increasing preference over conventional diagnostic approaches. In addition, the growing use of biocompatible materials and advanced patient monitoring technologies has further accelerated the adoption of smart capsules. Integration with wearable monitoring devices and digital health platforms is also expanding their role in modern healthcare.

The stomach segment accounted for 44% share in 2025. This segment holds a significant position due to the increasing application of smart pills in the monitoring and evaluation of stomach related conditions. Smart pill technologies designed for stomach assessment enable real time internal visualization and analysis of digestive health. These devices support accurate detection and monitoring of gastric disorders while minimizing patient discomfort compared with traditional diagnostic procedures. Growing demand for precise and early detection of stomach related diseases has further increased the adoption of this technology. In addition, improvements in sensor accuracy, imaging capabilities, and wireless communication systems have significantly enhanced the effectiveness of smart pill devices used for stomach diagnostics.

North America Smart Pills Market was valued at USD 503.5 million in 2025 and is expected to grow at a CAGR of 11.5% during 2026-2035. The region's strong growth is supported by its advanced healthcare infrastructure, widespread adoption of innovative medical technologies, and strong presence of digital healthcare solutions. Increasing prevalence of gastrointestinal conditions and chronic diseases continues to generate strong demand for advanced diagnostic and monitoring tools. In addition, the growing elderly population within the region is contributing to increased utilization of healthcare technologies that support early disease detection and continuous monitoring. The presence of established pharmaceutical and medical device manufacturers has also accelerated technological innovation within the industry. Continued investments in research, healthcare innovation programs, and supportive government initiatives further contribute to the steady expansion of the smart pills market across North America.

Major companies operating in the Global Smart Pills Market include Medtronic, Olympus Corporation, Otsuka Holdings, CapsoVision, ANX Robotica, Bodycap, Intromedic, Check-Cap, etectRx, and RF Co. Companies operating in the Smart Pills Market are implementing several strategic initiatives to strengthen their market presence and expand technological capabilities. Leading organizations are heavily investing in research and development to enhance sensor technologies, wireless communication systems, and data analytics platforms that improve the performance of ingestible medical devices. Many companies are also focusing on integrating artificial intelligence and connected health technologies to enable advanced diagnostic insights and remote patient monitoring. Strategic collaborations with healthcare providers, research institutions, and digital health companies are helping accelerate product development and clinical adoption. In addition, firms are expanding their global distribution networks and pursuing regulatory approvals in new markets to broaden their geographic reach.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Component trends
  • 2.1.4 Target area trends
  • 2.1.5 Application trends
  • 2.1.6 End use trends
• 2.2 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of gastrointestinal disorders
    • 3.2.1.2 Continuous improvements in smart pill technology
    • 3.2.1.3 Growing demand for non-invasive diagnostic tools
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory requirements
    • 3.2.2.2 High cost of devices
  • 3.2.3 Market opportunities
    • 3.2.3.1 Integration with digital health ecosystems
    • 3.2.3.2 Emerging market penetration
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology and innovation landscape
  • 3.5.1 Current technologies
  • 3.5.2 Emerging technologies
• 3.6 Pricing analysis (Driven by primary research)
• 3.7 Investment and funding landscape
• 3.8 Impact of AI and generative AI on the market
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Component, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Product
  • 5.2.1 Capsule
  • 5.2.2 Other products
• 5.3 Patient monitoring software

Chapter 6 Market Estimates and Forecast, By Target Area, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Stomach
• 6.3 Small intestine
• 6.4 Large intestine
• 6.5 Esophagus

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Capsule endoscopy
• 7.3 Targeted drug delivery
• 7.4 Vital sign monitoring

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Diagnostic centers
• 8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 ANX Robotica
• 10.2 Bodycap
• 10.3 CapsoVision
• 10.4 Check-Cap
• 10.5 etectRx
• 10.6 Intromedic
• 10.7 Medtronic
• 10.8 Otsuka Holdings
• 10.9 Olympus Corporation
• 10.10 RF Co.